Evidence map›Paper›PMID 30254458›Full record

ArticleOncoTargets and therapy2018

MicroRNA-300 suppresses metastasis of oral squamous cell carcinoma by inhibiting epithelial-to-mesenchymal transition.

Yuanyuan Kang, Ying Zhang, Yan Sun, Yan Wen, Fuli Sun

Abstract read
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuanyuan KangDepartment of Emergency and Oral Medicine, School of Stomatology, China Medical University, Shenyang 110002, China, kyandly@sina.com.
Ying ZhangDepartment of Emergency and Oral Medicine, School of Stomatology, China Medical University, Shenyang 110002, China, kyandly@sina.com.
Yan SunDepartment of Emergency and Oral Medicine, School of Stomatology, China Medical University, Shenyang 110002, China, kyandly@sina.com.
Yan WenDepartment of Emergency and Oral Medicine, School of Stomatology, China Medical University, Shenyang 110002, China, kyandly@sina.com.
Fuli SunDepartment of Emergency and Oral Medicine, School of Stomatology, China Medical University, Shenyang 110002, China, kyandly@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOral cancer is the sixth most prevalent form of cancer, with oral squamous cell carcinomas (OSCCs) exhibiting the highest morbidity of all head and neck cancers. However, the specific metastatic mechanism is not yet clear. MicroR-300 (miR-300) has been identified as a critical regulator in tumor development. In this study, we focused on the roles of miR-300 in regulating epithelial-mesenchymal transition (EMT) in OSCC.

methodsThe surgical specimens from cases of OSCC (N=120) were collected, and the miR-300 expression was tested and the results were analyzed for possible correlations with clinical characteristics, and the prognostic significance was assessed by Kaplan-Meier analysis and Cox proportional hazards regression in OSCC patients. In addition, the proliferation and invasion of OSCC cells were evaluated after transfection of miR-300 mimics or inhibitor. At last, the role of miR-300 in EMT was investigated.

resultsThe results showed that miR-300 levels were significantly lower in patients with OSCC than in controls and miR-300 levels in patients with OSCC were significantly associated with TNM classification. Kaplan-Meier analysis indicated that miR-300 with lower level had significantly decreased overall survival and disease-free survival of OSCC patients. In multivariate analysis, TNM stage, miR-300 expression and tobacco usage were the independent prognostic factors for overall survival and disease-free survival in OSCC. Moreover, in vitro experiments showed that miR-300 could inhibit the proliferation and invasion of OSCC cells. More importantly, miR-300 could inhibit the EMT process. In addition, we found that ET-1 could inhibit the expression of miR-300.

conclusionOur findings indicated that miR-300 could suppress metastasis of OSCC by inhibiting EMT. The present study indicates that miR-300 is a potential therapeutic agent for OSCC.

Indexed as

invasionmiR-300OSCCproliferationsuppresses

Identifiers

PMID30254458
PMCPMC6141125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.